Amphista Therapeutics
Amphista Therapeutics is an exciting spin out company founded by Advent Life Sciences and built on groundbreaking science from the laboratory of Professor Alessio Ciulli (University of Dundee), a world leader in the field of targeted protein degradation. Targeted protein degradation (TPD) hijacks the cell’s degradation machinery to modulate abundance of proteins that are responsible for disease progression. Our approach to protein degradation differentiates from traditional TPD technologies and is being developed to treat diseases with high unmet need.
Contact Amphista via their website
News archive
28/06/2021 Amphista Therapeutics Appoints New Head of Drug Discovery and Director of Chemistry...more
17/03/2021 Amphista Raises $53m in oversubscribed series b round...more
27/01/2021 Amphista blog: It's not Rocket Science...more
02/02/2021 Meet Amphista at 7 upcoming digital events...more
04/01/2020 Meet Amphista at Biotech showcase 11-15th January...more
01/11/2020 Amphista joins the BioPartner programme...more
